Liposomal nanocarriers for plasminogen activators

J 2016

Liposomal nanocarriers for plasminogen activators

KOUDELKA, Stepan; Robert MIKULÍK; Josef MAŠEK; Milan RAŠKA; Pavlína Turánek KNOTIGOVÁ et al.

Základní údaje

Originální název

Liposomal nanocarriers for plasminogen activators

Autoři

KOUDELKA, Stepan; Robert MIKULÍK; Josef MAŠEK; Milan RAŠKA; Pavlína Turánek KNOTIGOVÁ; Andrew D. MILLER a Jaroslav TURÁNEK

Vydání

Journal of Controlled Release, Amsterdam, Elsevier Science BV, 2016, 0168-3659

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 7.786

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00092488

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Fibrin; Liposomes; Platelets; Protein delivery; RGD peptide; Streptokinase; Stroke; Thrombus; Tissue plasminogen activator; Urokinase

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 12. 2016 15:25, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Several plasminogen activators (PAs) have been found effective in treating different thromboembolic diseases. However, administration of conventional thrombolytic therapy is limited by a low efficacy of present formulations of PAs. Conventional treatments using these therapeutic proteins are associated with several limitations including rapid inactivation and clearance, short half-life, bleeding complications or non-specific tissue targeting. Liposome-based formulations of PAs such as streptokinase, tissue-plasminogen activator and urokinase have been developed to improve the therapeutic efficacy of these proteins. Resulting liposomal formulations were found to preserve the original activity of PAs, promote their selective delivery and improve thrombus targeting. Therapeutic potential of these liposome-based PAs has been demonstrated successfully in various pre-clinical models in vivo. Reductions in unwanted side effects (e.g., hemorrhage or immunogenicity) as well as enhancements of efficacy and safety were achieved in comparison to currently existing treatment options based on conventional formulations of PAs. This review summarizes present achievements in: (i) preparation of liposome-based formulations of various PAs, (ii) development of PEGylated and targeted liposomal PAs, (iii) physicochemical characterization of these developed systems, and (iv) testing of their thrombolytic efficacy. We also look to the future and the imminent arrival of theranostic liposomal formulations to move this field forward.

Citovat

KOUDELKA, Stepan; Robert MIKULÍK; Josef MAŠEK; Milan RAŠKA; Pavlína Turánek KNOTIGOVÁ; Andrew D. MILLER a Jaroslav TURÁNEK. Liposomal nanocarriers for plasminogen activators. Journal of Controlled Release. Amsterdam: Elsevier Science BV, 2016, roč. 227, "neuvedeno", s. 45-57. ISSN 0168-3659. Dostupné z: https://doi.org/10.1016/j.jconrel.2016.02.019.

@article{1365669,
   author = {Koudelka, Stepan and Mikulík, Robert and Mašek, Josef and Raška, Milan and Knotigová, Pavlína Turánek and Miller, Andrew D. and Turánek, Jaroslav},
   article_location = {Amsterdam},
   article_number = {"neuvedeno"},
   doi = {https://doi.org/10.1016/j.jconrel.2016.02.019},
   keywords = {Fibrin; Liposomes; Platelets; Protein delivery; RGD peptide; Streptokinase; Stroke; Thrombus; Tissue plasminogen activator; Urokinase},
   language = {eng},
   issn = {0168-3659},
   journal = {Journal of Controlled Release},
   title = {Liposomal nanocarriers for plasminogen activators},
   volume = {227},
   year = {2016}
}

TY  - JOUR
ID  - 1365669
AU  - Koudelka, Stepan - Mikulík, Robert - Mašek, Josef - Raška, Milan - Knotigová, Pavlína Turánek - Miller, Andrew D. - Turánek, Jaroslav
PY  - 2016
TI  - Liposomal nanocarriers for plasminogen activators
JF  - Journal of Controlled Release
VL  - 227
IS  - "neuvedeno"
SP  - 45-57
EP  - 45-57
PB  - Elsevier Science BV
SN  - 01683659
KW  - Fibrin
KW  - Liposomes
KW  - Platelets
KW  - Protein delivery
KW  - RGD peptide
KW  - Streptokinase
KW  - Stroke
KW  - Thrombus
KW  - Tissue plasminogen activator
KW  - Urokinase
N2  - Several plasminogen activators (PAs) have been found effective in treating different thromboembolic diseases. However, administration of conventional thrombolytic therapy is limited by a low efficacy of present formulations of PAs. Conventional treatments using these therapeutic proteins are associated with several limitations including rapid inactivation and clearance, short half-life, bleeding complications or non-specific tissue targeting. Liposome-based formulations of PAs such as streptokinase, tissue-plasminogen activator and urokinase have been developed to improve the therapeutic efficacy of these proteins. Resulting liposomal formulations were found to preserve the original activity of PAs, promote their selective delivery and improve thrombus targeting. Therapeutic potential of these liposome-based PAs has been demonstrated successfully in various pre-clinical models in vivo. Reductions in unwanted side effects (e.g., hemorrhage or immunogenicity) as well as enhancements of efficacy and safety were achieved in comparison to currently existing treatment options based on conventional formulations of PAs. This review summarizes present achievements in: (i) preparation of liposome-based formulations of various PAs, (ii) development of PEGylated and targeted liposomal PAs, (iii) physicochemical characterization of these developed systems, and (iv) testing of their thrombolytic efficacy. We also look to the future and the imminent arrival of theranostic liposomal formulations to move this field forward.
ER  -

KOUDELKA, Stepan; Robert MIKULÍK; Josef MAŠEK; Milan RAŠKA; Pavlína Turánek KNOTIGOVÁ; Andrew D. MILLER a Jaroslav TURÁNEK. Liposomal nanocarriers for plasminogen activators. \textit{Journal of Controlled Release}. Amsterdam: Elsevier Science BV, 2016, roč.~227, ''neuvedeno'', s.~45-57. ISSN~0168-3659. Dostupné z: https://doi.org/10.1016/j.jconrel.2016.02.019.

Přehled o publikaci